December 21, 2016
Kiadis Pharma provides update on Phase II trial with cancer drug
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 21, 2016
Galapagos’s study of cystic fibrosis drug shows good results
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.
December 21, 2016
Takeda makes EUR10 million equity investment in TiGenix
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
December 21, 2016
Ipsen to sell Exelixis’s cabozantinib in Canada
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…
December 21, 2016
FDA accepts Vernalis and Tris Pharma’s NDA for cough drug
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…
December 21, 2016
Bayer and Leica Biosystems unite to fight cancer
Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on…
December 21, 2016
Premaitha buys Taiwanian bioinformatic company
Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene.
December 20, 2016
Allergan eats LifeCell for $2,9 billion
Allergan has acquired the regenerative medicine company LifeCell for $2.9 billion in cash.
December 20, 2016
BMS gets exclusive rights to study PsiOxus’s cancer drug
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
December 20, 2016
Japan to step up drug price reviews in bid to curbhealthcare costs
Japan said on Tuesday it will step up the pace and expand the scope of drug price reviews, one of the most aggressive measures it is taking to rein in ballooning healthcare costs for a rapidly ageing nation.